| 4 | Inhibition of levodopa metabolism to dopamine by honokiol short-chain fatty acid derivatives may enhance therapeutic efficacy in Parkinson's disease. (Cheng G, Hardy M, Feix JB, Kalyanaraman B) Sci Rep 2025 Jun 06;15(1):20004 2 Citations |
| 3 | Mitigating gut microbial degradation of levodopa and enhancing brain dopamine: Implications in Parkinson's disease. (Cheng G, Hardy M, Hillard CJ, Feix JB, Kalyanaraman B) Commun Biol 2024 May 30;7(1):668 17 Citations |
| 1 | L-DOPA and consolidation of fear extinction learning among women with posttraumatic stress disorder. (Cisler JM, Privratsky AA, Sartin-Tarm A, Sellnow K, Ross M, Weaver S, Hahn E, Herringa RJ, James GA, Kilts CD) Transl Psychiatry 2020 Aug 15;10(1):287 40 Citations |
| 2 | Mining Retrospective Data for Virtual Prospective Drug Repurposing: L-DOPA and Age-related Macular Degeneration. (Brilliant MH, Vaziri K, Connor TB Jr, Schwartz SG, Carroll JJ, McCarty CA, Schrodi SJ, Hebbring SJ, Kishor KS, Flynn HW Jr, Moshfeghi AA, Moshfeghi DM, Fini ME, McKay BS) Am J Med 2016 Mar;129(3):292-8 84 Citations |
| 1 | Interaction of levodopa and cues on voluntary reaching in Parkinson's disease. (Kelly VE, Hyngstrom AS, Rundle MM, Bastian AJ) Mov Disord 2002 Jan;17(1):38-44 35 Citations |
| 1 | Too many treatments for Parkinson's disease: how should they be used? (Reynolds NC Jr, Terry LC, Mark LP, Prieto TE, Mueller WR) WMJ 2000 Jun;99(3):57-61, 43 1 Citation |
| 1 | Effects of L-DOPA/carbidopa administration on the levels of L-DOPA, other amino acids and related compounds in the plasma, brain and heart of the rat. (Diederich C, Milakofsky L, Hare TA, Hofford JM, Dadmarz M, Vogel WH) Pharmacology 1997 Sep;55(3):109-16 11 Citations |
| 1 | Induction of mania by L-dopa in a nonbipolar patient. (Harsch HH, Miller M, Young LD) J Clin Psychopharmacol 1985 Dec;5(6):338-9 22 Citations |
© 2026 Clinical & Translational Science Institute